{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:52:43Z","timestamp":1793465563967,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"DAIICHI SANKYO COMPANY, LIMITED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105082","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:45:01Z","timestamp":1747277101000},"page":"105082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial"],"prefix":"10.1016","volume":"10","author":[{"given":"X.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roborel de Climens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andrzejuk-\u0106wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Mbanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2025.105082_bib1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and critical path institute workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"issue":"7-8","key":"10.1016\/j.esmoop.2025.105082_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000521826","article-title":"Significance of patient-reported outcomes for metastatic breast cancer patients","volume":"45","author":"Hillebrand","year":"2022","journal-title":"Oncol Res Treat"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105082_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12955-020-01389-x","article-title":"Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice","volume":"18","author":"Adamowicz","year":"2020","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105082_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105082_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf048","article-title":"Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician\u2019s choice of chemotherapy in patients with HER2-low mBC","author":"Ueno","year":"2025","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105082_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103691","article-title":"Real-world treatment patterns and outcomes in patients with HR+\/HER2\u2013 metastatic breast cancer treated with chemotherapy in the United States","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105082_bib10","article-title":"188P A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor-positive (HR+), HER2-low metastatic breast cancer (mBC)","volume":"9","author":"Ueno","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2025.105082_bib11","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105082_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105082_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","article-title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","volume":"31","author":"Bjelic-Radisic","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105082_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105082_bib16","first-page":"8367","article-title":"Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials","volume":"30","author":"Kawahara","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2025.105082_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.breast.2021.07.008","article-title":"Quality of life of therapies for hormone receptor positive advanced\/metastatic breast cancer: regulatory aspects and clinical impact in Europe","volume":"59","author":"Moscetti","year":"2021","journal-title":"Breast"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105082_bib18","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/1078-0432.CCR-17-2555","article-title":"Use of PRO measures to inform tolerability in oncology trials: implications for clinical review, IND safety reporting, and clinical site inspections","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105082_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105082_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.annonc.2023.04.516","article-title":"Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105082_bib22","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1470-2045(24)00128-1","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial","volume":"25","author":"Fehm","year":"2024","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105082_bib23","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105082_bib24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105082_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105082_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:41Z","timestamp":1762598681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009512"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105082","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105082"}}